| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $7,402,381 | 15 | 100 |
| Kalofonos Isabel | Chief Commercial Officer | 0 | $0 | 1 | $137,500 | $-137,500 |
| Knight Jeff E. | Chief Operating Officer | 0 | $0 | 1 | $244,964 | $-244,964 |
| Fust Matthew K | director | 0 | $0 | 1 | $716,000 | $-716,000 |
| Struthers Richard Scott | President & CEO | 0 | $0 | 2 | $773,017 | $-773,017 |
| Pizzuti Dana | Chief Med and Dev Officer | 0 | $0 | 8 | $2.19M | $-2.19M |
| Betz Stephen F. | Chief Scientific Officer | 0 | $0 | 2 | $3.34M | $-3.34M |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Crinetics Pharmaceuticals, Inc. have bought $0 and sold $7.4M worth of Crinetics Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Crinetics Pharmaceuticals, Inc. have bought $10.79M and sold $10.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $110,300 was made by Vivaldi Coelho Rogerio (director) on 2023‑06‑08.
| 2026-01-05 | Sale | Kalofonos Isabel | Chief Commercial Officer | 2,500 0.003% | $55.00 | $137,500 | +12.40% | |
| 2025-12-01 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0052% | $45.02 | $225,100 | +6.34% | |
| 2025-11-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0052% | $42.66 | $213,312 | +9.64% | |
| 2025-10-01 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0053% | $41.81 | $209,050 | +7.71% | |
| 2025-09-26 | Sale | Struthers Richard Scott | President & CEO | 4,000 0.0042% | $45.00 | $180,000 | -3.22% | |
| 2025-09-26 | Sale | Fust Matthew K | director | 16,000 0.0166% | $44.75 | $716,000 | -3.22% | |
| 2025-09-02 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0051% | $32.10 | $160,500 | +30.63% | |
| 2025-08-22 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 30,000 0.0314% | $30.43 | $912,900 | +39.10% | |
| 2025-08-20 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 6,492 0.0069% | $29.18 | $189,437 | +47.61% | |
| 2025-06-12 | Sale | Betz Stephen F. | Chief Scientific Officer | 97,483 0.1043% | $32.23 | $3.14M | +26.34% | |
| 2025-03-19 | Sale | Struthers Richard Scott | President & CEO | 17,338 0.0184% | $34.20 | $593,017 | -3.26% | |
| 2025-03-19 | Sale | Betz Stephen F. | Chief Scientific Officer | 5,770 0.0061% | $34.20 | $197,353 | -3.26% | |
| 2025-03-19 | Sale | Knight Jeff E. | Chief Operating Officer | 7,162 0.0076% | $34.20 | $244,964 | -3.26% | |
| 2025-03-19 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 2,515 0.0027% | $34.20 | $86,021 | -3.26% | |
| 2025-02-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0052% | $39.07 | $195,350 | -12.08% | |
| 2025-01-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 15,000 0.0158% | $52.09 | $781,350 | -35.56% | |
| 2024-12-02 | Sale | Struthers Richard Scott | President & CEO | 10,000 0.0108% | $57.57 | $575,700 | -40.31% | |
| 2024-11-22 | Sale | Knight Jeff E. | Chief Operating Officer | 501 0.0005% | $56.52 | $28,317 | -38.90% | |
| 2024-10-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 14,375 0.0194% | $54.63 | $785,306 | -35.09% | |
| 2024-09-26 | Sale | Wilson Marc | CFO | 25,000 0.0317% | $51.11 | $1.28M | -32.28% |
| Struthers Richard Scott | President & CEO | 106000 0.1034% | $5.93M | 2 | 16 | +35.75% |
| Betz Stephen F. | Chief Scientific Officer | 99713 0.0973% | $5.58M | 0 | 49 | |
| Knight Jeff E. | Chief Operating Officer | 87491 0.0853% | $4.9M | 0 | 6 | |
| Pizzuti Dana | Chief Med and Dev Officer | 66837 0.0652% | $3.74M | 0 | 17 | |
| Fust Matthew K | director | 22836 0.0223% | $1.28M | 0 | 9 | |
| Kalofonos Isabel | Chief Commercial Officer | 834 0.0008% | $46,695.66 | 0 | 1 | |
| EDELMAN JOSEPH | 5321032 5.1907% | $297.92M | 1 | 0 | <0.0001% | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5163517 5.037% | $289.11M | 5 | 0 | +3.73% |
| Vivo Capital VIII, LLC | 10 percent owner | 298625 0.2913% | $16.72M | 1 | 13 | +10.46% |
| Madan Ajay | Chief Development Officer | 176995 0.1727% | $9.91M | 0 | 2 | |
| Wilson Marc | CFO | 111092 0.1084% | $6.22M | 0 | 8 | |
| 5AM Ventures IV, L.P. | 94489 0.0922% | $5.29M | 1 | 3 | +10.46% | |
| Krasner Alan Seth | Chief Medical Officer | 43210 0.0422% | $2.42M | 1 | 2 | +10.46% |
| Hassard James | Chief Commercial Officer | 29259 0.0285% | $1.64M | 0 | 2 | |
| Okey Stephanie | director | 6000 0.0059% | $335,940.00 | 0 | 1 | |
| Vivaldi Coelho Rogerio | director | 5000 0.0049% | $279,950.00 | 1 | 0 | +51.5% |
$108,876,545 | 67 | 72.81% | $8.37B | |
$224,382,625 | 44 | 27.62% | $4.71B | |
$477,065,869 | 34 | 82.05% | $5.29B | |
$103,944,213 | 17 | 5.95% | $6.78B | |
$11,859,102 | 17 | 18.62% | $7.65B | |
$74,605,681 | 14 | 47.06% | $5.1B | |
$75,296,863 | 13 | 33.79% | $5.49B | |
$57,686,748 | 13 | 21.11% | $5.82B | |
$9,976,473 | 12 | 29.52% | $6.71B | |
Crinetics Pharmaceuticals, Inc. (CRNX) | $91,269,919 | 12 | 12.86% | $5.74B |
$2,477,801 | 11 | 4.98% | $5.22B | |
$11,898,979 | 10 | 54.58% | $8.27B | |
$35,908,794 | 10 | 126.31% | $5.13B | |
$3,073,199 | 10 | 16.77% | $4.95B | |
$20,499,451 | 9 | 71.54% | $5.92B | |
$55,713,031 | 8 | -0.36% | $5.44B | |
$2,246,813 | 6 | 70.15% | $4.85B | |
$105,414,951 | 5 | 10.07% | $7.58B | |
$41,376,000 | 4 | -12.07% | $6.1B |
| Increased Positions | 125 | +49.6% | 10M | +9.7% |
| Decreased Positions | 113 | -44.84% | 7M | -6.75% |
| New Positions | 38 | New | 1M | New |
| Sold Out Positions | 37 | Sold Out | 1M | Sold Out |
| Total Postitions | 264 | +4.76% | 108M | +2.96% |
| Fmr Llc | $662,982.00 | 14.93% | 14.19M | +61,499 | +0.43% | 2025-09-30 |
| Vanguard Group Inc | $428,520.00 | 9.65% | 9.17M | -86,003 | -0.93% | 2025-09-30 |
| Wellington Management Group Llp | $391,690.00 | 8.82% | 8.38M | +3M | +44.34% | 2025-09-30 |
| Blackrock, Inc. | $354,522.00 | 7.99% | 7.59M | +167,882 | +2.26% | 2025-09-30 |
| Driehaus Capital Management Llc | $302,886.00 | 6.82% | 6.48M | +81,588 | +1.27% | 2025-09-30 |
| Farallon Capital Management Llc | $269,637.00 | 6.07% | 5.77M | +1M | +24.19% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $247,961.00 | 5.59% | 5.31M | -284,256 | -5.08% | 2025-09-30 |
| Ecor1 Capital, Llc | $200,384.00 | 4.51% | 4.29M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $180,321.00 | 4.06% | 3.86M | +448,471 | +13.15% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $119,198.00 | 2.69% | 2.55M | +207,221 | +8.84% | 2025-09-30 |